Nov 16th, 2 PM: Distinguished Guest Lecture by Dr. Özlem Türeci: RNA-based therapeutics and personalized neoantigen cancer vaccines

Dr. Özlem Türeci (photo: BioNTech)
Dr. Özlem Türeci (photo: BioNTech)

Dr. Özlem Türeci, Chief Medical Officer, BioNTech and Professor, Mainz University Medical Ctr & Helmholtz Institute for Translational Oncology visits Radiumhospitalet/OCC on November 16th to give a lecture.
Time and place: , Radiumhospitalet/OCC, Kaare Norum Auditorium
NB: Registration necessary
Dr. Tureci will also give a talk at 1800 the same day in the Norwegian Academy of Science and Letters with title: “Vaccines: mRNA vaccine technology - COVID-19, Cancer & beyond”. Registration necessary also here.

Abstract from dr. Türeci:
My talk at Oslo University Hospital will be a scientific, technological one directed to an expert scientific and clinical audience with strong background in immunology and oncology.
I may cover 2 topics if time allows: preclinical-clinical development of RNA cancer vaccines and a new CAR T cell.
 
 
From the Nobel Committee at Karolinska Institutet on awarding the Nobel Prize in Physiology or Medicine 2023 to Katalin Karikó og Drew Weissmann:
"When the pandemic broke in early 2020, mRNA companies acted quickly to develop COVID-19 vaccines. BioNTech and Moderna chose to use mRNA with modified bases building on the discoveries by Karikó and Weissmann. BioNTech, with Uğur Şahin and Özlem Türeci in the lead, worked in partnership with Pfizer.”
"This essential work served humanity during the COVID-19 pandemic." 
Read more about the Nobel Prize in Medicine or Physiology 2023
 
See also announcement from PRIMA - a Center of Excellence in Precision Immunotherapy:
 
Organizers: 
Institute for Cancer Research, Oslo University Hospital, CoE PRIMA, University of Oslo and Norwegian Society for Immunology

NB: Dr. Tureci will also give a talk at 1800 in the Norwegian Academy of Science and Letters with the title:
Vaccines: mRNA vaccine technology - COVID-19, Cancer & beyond

The Norwegian Academy of Science and Letters talk will cover the development of mRNA vaccine technology and the journey from cancer vaccines to the Pfizer/BioNTech Covid vaccine.
 
NB Registration by email to Line Therese Nævestad: l.t.navestad@dnva.no

 

 
Page visits: 1177